Background. Fidaxomicin is an approved therapy for Clostridium difficile-associated diarrhea (CDAD) in adults. The safety of fidaxomicin in children has not been reported.
including in populations lacking traditional risk factors, such as older age, previous hospitalization, or antibiotic exposure [5] . The heightened severity of CDAD is a result of the emergence of resistant and potentially hypervirulent strains [3, 6] .
Several studies have found that the incidence of pediatric CDAD in the United States has also risen over the past 3 decades in both the hospital and community settings [7] [8] [9] [10] [11] . Between 1997 and 2006, the rate of pediatric CDAD-related hospitalizations rose from 7.2 to 12.8 per 10 000 hospitalizations [7] ; however, clinical studies of CDAD therapies in pediatric populations remain limited. Currently, the only US Food and Drug Administration-approved agent for CDAD treatment in children is orally administered vancomycin, but the American Academy of Pediatrics recommends using metronidazole as first-line therapy for the first mild-to-moderate CDAD episode and for the first recurrence [12] . Vancomycin and metronidazole are associated with high rates of recurrence because of their broad antimicrobial spectrum, which results in further perturbation of the intestinal microbiota [13] . Likewise, both of them have limitations, including poor palatability for suspension and risk of vancomycin-resistant enterococci with oral vancomycin use [14] . Fecal transplantation has resulted in high success rates for preventing recurrence, but questions remain over its safety and best method of administration [13] .
Fidaxomicin, a narrow-spectrum 18-membered macrocyclic antibiotic, was approved in the United States in 2011 for the treatment of CDAD in adults [15] . The efficacy and safety of fidaxomicin versus vancomycin in adult patients were compared in 2 large randomized clinical trials [16, 17] . These trials demonstrated that fidaxomicin was associated with recurrence rates lower than those of vancomycin. This phase 2a study was conducted to assess the safety, tolerability, and pharmacokinetics (PK) of fidaxomicin in children aged 6 months to <18 years with CDAD. Although the American Academy of Pediatrics does not recommend treatment in children younger than 12 months, in whom high rates of C difficile colonization are found, children older than 6 months were eligible for this study because, although uncommon, the disease does likely occur in this age group [12] . The secondary objective of the study was to evaluate the efficacy of fidaxomicin in children by assessing clinical response after 10 days of treatment and sustained clinical response 28 days after treatment.
METHODS

Study Design
This phase 2a multicenter open-label single-arm study enrolled children at 11 centers across the United States and Canada between October 2012 and March 2014 (protocol number OPT-80-206; ClinicalTrials.gov identifier, NCT01591863). Patients ≥6 years of age received a fidaxomicin tablet (200 mg) orally every 12 hours for 10 days; those who were unable to swallow a tablet received fidaxomicin as an oral suspension at the same dose and frequency. Patients aged 6 months to <6 years received a weight-based dose of an oral suspension, 32 mg/kg per day, up to 400 mg/day (the adult dose), as a divided dose every 12 hours. After the 10-day course of treatment, patients were followed for an additional 28 days to evaluate clinical response and adverse events (AEs). This study was conducted in accordance with the Declaration of Helsinki. The study protocol and any amendments were approved by an institutional review board/independent ethics committee at each study site, and written informed consent was obtained from the parent or legal guardian of each patient before the study commenced. Further details of the study methods are provided in the study protocol in the Supplementary Data.
Patients
Eligible participants included children between 6 months and <18 years of age and diagnosed with CDAD, defined by a positive fecal assay (either a toxin-based assay or nucleic acid amplification test) result for toxigenic C difficile within 48 hours of enrollment and either >3 watery bowel movements (BMs) (patients aged 6-23 months) or >3 unformed BMs (patients 2 to <18 years of age) in the 24 hours before enrollment. Exclusion criteria were need for concurrent use of other drugs for the treatment of CDAD, concurrent use of P-glycoprotein inhibitors, fulminant colitis, or a history of inflammatory bowel disease. Disease severity at enrollment was defined as mild (4-5 unformed BMs/day or a white blood cell [WBC] count of ≤12 000/mL), moderate (6-9 unformed BMs/day or a WBC count of 12 001-15 000/mL), or severe (≥10 unformed BMs/day or a WBC count of ≥15 001/mL). The more severe of the disease categories was chosen as the default for cases in which signs and symptoms overlapped categories.
Safety Assessments
Safety evaluations included documenting AEs, performing clinical laboratory tests (including hematology, urinalysis, and clinical chemistry), electrocardiography, and a physical examination, and documenting vital signs. AEs (from the time of informed consent to 30 days after the last dose of study medication) were classified according to the Medical Dictionary for Regulatory Activities (MedDRA version 15.0). The severity (mild, moderate, or severe) and causality (not related or unlikely, possibly, or definitely related to the study medication) of the AEs were assessed by the investigator at each site. Serious AEs (SAEs) were those that necessitated hospitalization, were life threatening, or were fatal.
PK Evaluation
Three plasma samples were collected on a single day between days 5 and 10: 0 to 2 hours before dosing, 1 to 2 hours after dosing, and 3 to 5 hours after dosing (time points that are clustered around the maximal concentration, [T max ], window for fidaxomicin in adults). Fecal samples were collected on day 10 or the last day of treatment. Plasma and fecal concentrations of fidaxomicin and its primary metabolite, OP-1118, were measured using validated liquid chromatography/tandem mass spectroscopy methods [18] . Plasma samples were assayed by Tandem Labs (Salt Lake City, UT) and fecal samples by MicroConstants, Inc (San Diego, CA).
Efficacy Assessments
The main efficacy outcome was clinical response assessed at day 10. For patients aged 6 to 23 months, clinical response was defined as the absence of watery diarrhea for 2 consecutive days during treatment, remaining well before the time of fidaxomicin discontinuation, and not requiring further CDAD therapy within 2 days after completion of treatment. For patients aged 2 to 17 years, clinical response was defined as an improvement in the number and character of BMs for 2 consecutive days during treatment, remaining well through the end of fidaxomicin use, and not requiring further CDAD therapy within 2 days after the completion of treatment. Recurrence was defined as the return of diarrhea after a positive clinical response within 28 days after treatment, presence of a toxigenic strain of C difficile in the stool, and study investigator-determined need for retreatment. Patients who withdrew from the study during the 28-day follow-up period for any reason were also counted as recurrences. Sustained response was defined as a positive clinical response at the end of treatment without proven or suspected CDAD recurrence in the 28 days after treatment.
Statistical Analysis
Patients were stratified into 1 of 4 groups on the basis of age at enrollment: 6 to 23 months, 2 to <6 years, ≥6 to <12 years, and ≥12 to <18 years. Summarized data and descriptive statistics are presented; no inferential analyses were performed. The safety population included all patients with evaluable data who had received at least 1 dose of fidaxomicin. The modified intent-totreat (mITT) population included all patients with CDAD confirmed by a positive toxin A and/or B test assay result within 24 hours before enrollment and who received at least 1 dose of fidaxomicin. In addition, plasma PK and fecal PK populations included all dosed patients with evaluable plasma and fecal PK data, respectively. All statistical summaries were generated using SAS 9.3 software (SAS Institute, Inc, Cary, NC). The LIFETEST procedure in SAS was used to estimate the survival function (in days) for time to recurrence using the Kaplan-Meier method.
RESULTS
Patients
Of 40 patients enrolled, 38 patients (11 months to 17 years of age) were treated with fidaxomicin ( Figure 1 ). Demographics and baseline characteristics of the mITT population are presented in Tables 1 and 2 treatment-related, and 1 (urticaria in a patient 2 to <6 years of age) was regarded as "definitely" treatment-related. Three (7.9%) patients were withdrawn from the study (2 during the treatment period and 1 during follow-up) because of their AE, including the child with urticaria ascribed to study treatment, a child with gas pain (considered not related to study medication), and a child with increased body temperature and mild tachycardia (possibly related). Of the 9 patients who experienced an SAE, the symptom of 8 (88.9%) of them was either resolved or resolving at the end of the study. There was 1 fatal SAE (also reported as severe [septic shock and respiratory failure]) that occurred in a 17-monthold child with underlying acute lymphocytic leukemia. None of the SAEs were considered related to treatment. Few patients had clinically significant changes from baseline in their clinical laboratory test results, electrocardiographic parameters, or vital signs. Increased blood pressure, tachycardia, and increased body temperature (1 patient each) were reported as treatment-emergent AEs (TEAEs); hypertension and pyrexia were reported as TEAEs for 2 and 4 patients, respectively.
PK Outcomes
Three-to 5-hour postdose fidaxomicin plasma levels across all age groups ranged from 0.6 to 87.4 ng/mL, and OP-1118 (the primary metabolite of fidaxomicin) levels were 2.4 to 882.0 ng/mL. The mean (standard deviation [SD]) postdose plasma levels were 13.4 ng/mL (15.5 ng/mL) for fidaxomicin and 60 ng/mL (152.2 ng/mL) for OP-1118. Figure 2A shows the peak postdose plasma concentrations of fidaxomicin and OP-1118. No clear trend between the age groups was observed, despite younger patients receiving relatively higher doses according to weight (Figure 2A) . A detectable level of fidaxomicin was found in each fecal sample collected from the 30 patients. The concentrations ranged from 268 to 11 500 µg/g of stool (overall mean
Concentrations of OP-1118 ranged from below the limit of quantification (2 patients) to 2540 µg/g of stool (mean [SD], 865.5 µg/g [614.2 µg/g]) for the 28 patients with a detectable level. A trend toward higher mean concentrations was noted in the youngest age group (Figure 2B ), although variability was highest in this age group. 
Efficacy Outcomes
The clinical response rate was 92.1% (35 of 38). The sustained response rate was 65.8% (25 of 38) and was 50% or higher in each age group (Table 5) . A recurrence within 28 days after a clinical response was exhibited in 11 of the 35 (31.4%) patients with clinical response. All 11 of these patients had previous episodes of CDAD and had varied medical histories. Rates of positive clinical outcomes and recurrence were similar across the age groups. The times to recurrence according to age group are shown in Figure 3 .
DISCUSSION
In this open-label pediatric study, fidaxomicin was well tolerated and had a safety profile consistent with that reported for adults [16, 17] . The overall PK profile of fidaxomicin in pediatric patients was similar to that seen in adults. The high fecal concentrations of fidaxomicin (mean across all age groups, 3227.9 µg/g) were consistently higher than the in vitro minimum inhibitory concentration range (0.015-0.25 µg/mL) for fidaxomicin against C difficile isolates [19] and higher than those found in adults (mean, 1225.1 µg/g) [17] , particularly at younger ages. It should be noted that for fecal concentrations of fidaxomicin and OP-1118, data from the youngest age group were the most variable. This increased variability could be explained by the sampling of stools from diapers, which possibly resulted in dilution of the sample by urine (potentially explaining the 2 patients without a detectable fecal level of OP-1118) or, conversely, concentration of the watery stool by absorption. Consistent with observations in adult studies (unpublished data), no correlation between fecal fidaxomicin concentration and efficacy outcome was observed.
Previous studies in adults with CDAD revealed low systemic absorption for fidaxomicin, that is, a mean (SD) plasma level of 28.5 ng/mL (33.4 ng/mL) 3 to 5 hours after 200-mg (twice-daily) dosing on day 10 (mean [SD] plasma level of OP-1118, 85.6 ng/mL [131 ng/mL]) [20] . Plasma levels in the pediatric patients in this study were slightly lower (13.4 ng/mL [15.5 ng/mL] and 60.0 ng/mL [152.2 ng/mL], respectively). However, additional studies are required to confirm these results in a larger sample size, and a phase 3 follow-up study is currently under way to determine the efficacy and safety of fidaxomicin and vancomycin in a larger pediatric population. Together with the observed high fecal concentrations, our results indicate desirably low systemic absorption of fidaxomicin in children.
In this study, fidaxomicin resulted in a high clinical response rate in children but a somewhat higher recurrence rate (31.4%) than those found in 2 adult phase 3 studies (12.7% [16] and 15.4% [17] ) in which similar definitions of recurrence were used. However, approximately 60% of the pediatric patients in our study had experienced previous episodes of CDAD (42.1% of the children had had multiple previous episodes), which is a known risk factor for additional recurrences [21] . In adult studies, recurrence rates of 18.9% and 21.4% were found in adults with 1 previous episode of C difficile infection [16, 17] . It is important to note that those with 2 or more CDAD episodes in the preceding 3 months were excluded from the adult studies of fidaxomicin, which suggests that our study population was at an increased risk of recurrence compared with those in previous adult studies [16, 17, 20] . The complex medical history of many of the pediatric patients in our study might have also predisposed them to CDAD recurrence; 37% were inpatients, 24% had a neoplasm, 24% were undergoing tube feeding, and 26% were taking concomitant antibiotics, all of which are recognized risk factors for recurrence [22] [23] [24] . Another factor that potentially contributed to the high recurrence rate was that each withdrawal during the follow-up period was counted as a recurrence. However, only 1 patient was imputed in this way as having had a recurrence. Also, because we focused primarily on safety and PK, the study was not sized to provide accurate estimates of recurrence rates. A phase 3 study (ClinicalTrials.gov identifier, NCT02218372) to further characterize CDAD recurrence rates is being conducted in a larger pediatric population, and the results might better reflect the full spectrum of children who develop CDAD after antibiotic exposure. It would also be useful to determine whether pediatric use of fidaxomicin is associated with lower recurrence rates than those found with vancomycin, as has been observed in adults [16, 17] . In addition, it would be helpful to ascertain whether prolonging the duration of fidaxomicin therapy to 14 days could reduce the risk of recurrence in pediatric patients.
It should be noted that the clinical outcomes were not assessed in relation to the strain types that caused the initial and subsequent infections. Therefore, an important limitation is that this study did not distinguish recurrence caused by relapse of the current infection or by newly acquired infection. These data would help determine whether recurrent infections were related to the acquisition of new strains versus a failure of fidaxomicin to eradicate the initial infection successfully.
No child <11 months of age was enrolled in this study; C difficile testing and treatment of children <1 year of age are discouraged by the American Academy of Pediatrics, except for those with Hirschsprung disease [12] . In addition, children <12 months old exposed to C difficile nearly always remain asymptomatic despite colonization with toxin-producing strains of C difficile [25] . Thus, the clinical significance of C difficile in children <24 months old has been questioned [26] .
Because of the controversy regarding C difficile infection in young children, an international expert panel recently reported a lack of an unmet need for CDAD therapy in infants and a poor ability to discriminate disease from colonization and therefore recommended that clinical trials exclude children younger than 2 years [27] .
Another limitation of this study is that we did not assess other causes of diarrhea, which might have had an impact on efficacy outcomes, especially in younger children, who commonly have viral coinfections and might also be colonized with C difficile without it being the primary cause of diarrhea [28] . Likewise, many of the patients in this study had risk factors for noninfectious diarrhea, such as cancer, feeding-tube insertion, and medication use [29, 30] .
Last, there are special challenges in studying C difficile in young patients. Urine contamination of fecal samples collected from diapers in the youngest age group might limit the accuracy of stool fidaxomicin and OP-1118 quantitation.
CONCLUSIONS
In this study, fidaxomicin was well tolerated in children with CDAD across all included age groups. The PK profile (low plasma levels and high fecal concentrations) was similar to that recorded in adults and reflects the low absorption of fidaxomicin. PK, safety, and efficacy data from this study support the continued development of fidaxomicin for use in pediatric populations.
Supplementary Data
Supplementary materials are available at Journal of the Pediatric Infectious Diseases Society online.
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